Gerald Clarke | 10/07/2013
In 2008 and 2009, Genzyme sites were affected by vesivirus infection. This shut down two sites for decontamination. In this candid interview, Lada Laenen, Managing Principal Scientist, Head, Cell Culture and Microbiology, Genzyme, a Sanofi Company, discusses how this affected Genzyme. She explains what they have changed to avoid this happening again. Dr. Laenen also describes the company's creation of an 'organisms of concern' list, ensuring quality i...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More